Claims
- 1. A method of treating or preventing thrombin-induced coagulation of blood comprising administering to a human or animal patient in need thereof an SdrG protein in an amount effective to treat or prevent thrombin-induced coagulation of the blood.
- 2. The method according to claim 1 wherein the SdrG protein is the ligand-binding A region of SdrG.
- 3. The method according to claim 1 wherein the A region has the sequence of residues 50-597 of SdrG.
- 4. The method according to claim 1 wherein the SdrG protein is a recombinant protein.
- 5. The method according to claim 1 wherein the method is used to treat a disease condition selected from the group consisting of stroke, myocardial infarction, sickle-cell crisis and venous thrombosis.
- 6. The method according to claim 1 wherein the method is used to reduce the concentration of plasma fibrinogen in the patient's blood.
- 7. The method according to claim 1 wherein the method is used to interfere with or inhibit the release of fibrinopeptide B from fibrinogen.
- 8. The method according to claim 1 further comprising the step of administering ancrod in an amount effective to interfere or inhibit the release of fibrinopeptide A from fibrinogen.
- 9. A method of treating or preventing thrombin-induced coagulation comprising administering to a human or animal patient in need thereof a S. epidermidis fibrinogen-binding protein from that can bind to the fibrinogen Bβ chain in an amount effective to treat or prevent thrombin-induced coagulation.
- 10. A method according to claim 9 wherein the fibrinogen-binding protein is selected from the group consisting of SdrG, Fbe, and their respective A regions.
- 11. A method according to claim 9 wherein the fibrinogen-binding protein binds at the site of residues 6-20 of the fibrinogen Bβ chain.
- 12. A method of inhibiting thrombin binding to fibrinogen comprising administering to a human or animal patient in need thereof an SdrG protein in an amount effective to inhibit thrombin binding to fibrinogen.
- 13. A method of interfering with or inhibiting the release of fibrinopeptide B from fibrinogen comprising administering to a human or animal patient in need thereof an SdrG protein in an amount effective to interfere with or inhibit the release of fibrinopeptide B from fibrinogen.
- 14. A therapeutic composition for treating or preventing thrombin-induced coagulation comprising SdrG in an amount effective to treat or prevent thrombin-induced coagulation, and a pharmaceutically acceptable vehicle, carrier or excipient.
- 15. A method of treating or preventing thrombin-induced coagulation comprising administering to a human or animal patient in need thereof the composition of claim 14 in an amount effective to treat or prevent thrombin-induced coagulation.
- 16. A method for treating a disease condition selected from the group consisting of stroke, myocardial infarction, sickle-cell crisis and venous thrombosis comprising administering to a human or animal patient in need thereof an effective amount of the composition of claim 14.
- 17. A method for reducing plasma fibrinogen concentration in blood comprising administering to a human or animal an effective amount of the composition according to claim 14.
- 18. A therapeutic composition for treating or preventing thrombin-induced coagulation comprising a fibrinogen-binding protein from S. epidermidis which can bind to the Bβ chain of fibrinogen in an amount effective to treat or prevent thrombin-induced coagulation, and a pharmaceutically acceptable vehicle, carrier or excipient.
- 19. The therapeutic composition according to claim 18 wherein the fibrinogen-binding protein is selected from the group consisting of SdrG, Fbe and their respective A regions.
- 20. The therapeutic composition according to claim 18 wherein the SdrG A region has the sequence of residues 50-597 of SdrG.
- 21. The therapeutic composition according to claim 18 wherein the fibrinogen-binding protein is a recombinant protein.
- 22. The therapeutic composition according to claim 18 wherein the fibrinogen-binding protein binds at the site of residues 6-20 of the fibrinogen Bβ chain
- 23. A method of treating or preventing thrombin-induced coagulation comprising administering to a human or animal patient in need thereof the composition of claim 18 in an amount effective to treat or prevent thrombin-induced coagulation.
- 24. A method for treating a disease condition selected from the group consisting of stroke, myocardial infarction, sickle-cell crisis and venous thrombosis comprising administering to a human or animal patient in need thereof an effective amount of the composition of claim 18.
- 25. A method for reducing plasma fibrinogen concentration in blood comprising administering to a human or animal an effective amount of the composition according to claim 18.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Patent Application No. 60/290,072, filed May 11, 2001.
STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0002] The subject matter of this application was supported by Grant No. AI20624 from the National Institutes of Health.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60290072 |
May 2001 |
US |